The Institute for Public Health Surveillance (InVS) and the National Cancer Institute (INCa) have just published the third report on the survival of adults with cancer in mainland France. This study, carried out over the period 1989-2013, covers 53 cancers.
The observed trends are considered “encouraging” by the authors because the medium-term survival of patients with the three most frequent solid tumors has improved: Prostate cancer : +22 points with 94% survival; colon-rectal cancer : +9 points with 63% survival; breast cancer: +7 points with 87% survival.
“The improvement in prostate cancer survival results from a combination of different factors: diagnostic practices, therapeutic progress and more effective treatment because it is earlier. That of colon cancer is mainly explained by a decrease in operative mortality and progress in treatment.
Finally, the increase in breast cancer survival is attributed to the major therapeutic advances made in the early 2000s, and to an increase in the proportion of cancers discovered at an early stage in connection with the development of screening practices “ underline the authors of this study, available online.
The fact that breast tumors are among the cancers with a good prognosis should not obscure the fact that, due to their frequency, they remain the leading cause of death from cancer in women. The second being now lung cancer. Even if the survival rate for this cancer is improving (+ 4 points) there is still a very poor prognosis with only 17% survival rate. “At present, the best weapon to fight against mortality linked to this cancer is the fight against smoking. The same is true for other cancers linked to risky behavior, associated with tobacco and alcohol. such as cancers of the aerodigestive tract and certain digestive cancers, which makes it essential to pursue preventive actions “ insist the authors.
A second volume of the report takes stock of the survival rate of hematologic malignancies. The three most frequent see their survival rate improve: diffuse large B-cell lymphoma: +18 points, with 60% survival; Multiple myeloma and plasmacytoma: +11 points with 54% survival and chronic lymphocytic leukemia / lymphocytic lymphoma: +8 points with 85% survival.
“The improvement in the survival of CLL / lymphocytic lymphoma is probably linked to a better understanding of the disease, in particular a better identification of prognostic factors, but also to changes in management. And the marked increase in the disease. survival of diffuse large B-cell lymphoma in all age groups is largely linked to the introduction of innovative treatments (monoclonal antibodies) at the level of certain multidrug therapies “ add the authors.
Read also :
Breast cancer: in case of recurrence, longer survival times
After chemo, it takes 9 months for the immune system to recover
